Terayama Y - Search Results

1

Response to Letter. "Romosozumab and cardiovascular safety- should we learn lessons from Pioglitazone?.".

Tominaga A, Wada K, Okazaki K, Nishi H, Terayama Y, Kato Y. Tominaga A, et al. Among authors: terayama y. Osteoporos Int. 2022 Jun;33(6):1401-1402. doi: 10.1007/s00198-022-06300-6. Epub 2022 Feb 18. Osteoporos Int. 2022. PMID: 35181822 No abstract available.

2

Optimal Measurement Level and Ulnar Nerve Cross-Sectional Area Cutoff Threshold for Identifying Ulnar Neuropathy at the Elbow by MRI and Ultrasonography.

Terayama Y, Uchiyama S, Ueda K, Iwakura N, Ikegami S, Kato Y, Kato H. Terayama Y, et al. J Hand Surg Am. 2018 Jun;43(6):529-536. doi: 10.1016/j.jhsa.2018.02.022. Epub 2018 Apr 3. J Hand Surg Am. 2018. PMID: 29622409

3

Early clinical effects, safety, and appropriate selection of bone markers in romosozumab treatment for osteoporosis patients: a 6-month study.

Tominaga A, Wada K, Kato Y, Nishi H, Terayama Y, Okazaki K. Tominaga A, et al. Among authors: terayama y. Osteoporos Int. 2021 Apr;32(4):653-661. doi: 10.1007/s00198-020-05639-y. Epub 2020 Sep 26. Osteoporos Int. 2021. PMID: 32979066

4

Early clinical effects, safety, and predictors of the effects of romosozumab treatment in osteoporosis patients: one-year study.

Tominaga A, Wada K, Okazaki K, Nishi H, Terayama Y, Kato Y. Tominaga A, et al. Among authors: terayama y. Osteoporos Int. 2021 Oct;32(10):1999-2009. doi: 10.1007/s00198-021-05925-3. Epub 2021 Mar 26. Osteoporos Int. 2021. PMID: 33770201 Free PMC article.

5

Effect of the duration of previous osteoporosis treatment on the effect of romosozumab treatment.

Tominaga A, Wada K, Okazaki K, Nishi H, Terayama Y, Kodama Y, Kato Y. Tominaga A, et al. Among authors: terayama y. Osteoporos Int. 2022 Jun;33(6):1265-1273. doi: 10.1007/s00198-021-06261-2. Epub 2022 Jan 21. Osteoporos Int. 2022. PMID: 35059774

6

Nonresponder Considerations for Romosozumab Treatment.

Tominaga A, Wada K, Okazaki K, Nishi H, Terayama Y, Shimamoto S, Kodama Y, Kato Y. Tominaga A, et al. Among authors: terayama y. Calcif Tissue Int. 2023 Aug;113(2):157-165. doi: 10.1007/s00223-023-01087-y. Epub 2023 May 3. Calcif Tissue Int. 2023. PMID: 37138124

7

[Survey on the Size of Oral Anticancer Drugs].

Hikita E, Terayama Y, Yasu T. Hikita E, et al. Among authors: terayama y. Gan To Kagaku Ryoho. 2024 Dec;51(12):1221-1226. Gan To Kagaku Ryoho. 2024. PMID: 39721783 Japanese.

8

Eosinophilic inflammation that begins in the juvenile stage causes hydronephrosis and urothelial cancer in mutant mice.

Ozaki K, Terayama Y, Kojima MI, Matsuura T, Ozaki K. Ozaki K, et al. Among authors: terayama y. Sci Rep. 2024 Dec 4;14(1):30217. doi: 10.1038/s41598-024-81013-w. Sci Rep. 2024. PMID: 39633023 Free PMC article.

9

Voriconazole trough levels after switching from an intravenous to oral formulation in a patient with short bowel syndrome.

Ishida R, Yasu T, Hayakawa M, Terayama Y. Ishida R, et al. Among authors: terayama y. Int J Clin Pharmacol Ther. 2024 Dec;62(12):579-581. doi: 10.5414/CP204679. Int J Clin Pharmacol Ther. 2024. PMID: 39445387 No abstract available.

10

Glucose metabolism and smaller hippocampal volume in elderly people with normal cognitive function.

Shima A, Noguchi-Shinohara M, Shibata S, Usui Y, Tatewaki Y, Thyreau B, Hata J, Ohara T, Honda T, Taki Y, Nakaji S, Maeda T, Mimura M, Nakashima K, Iga JI, Takebayashi M, Nishijo H, Ninomiya T, Ono K; Japan Prospective Studies Collaboration for Aging and Dementia (JPSC-AD) study group. Shima A, et al. NPJ Aging. 2024 Sep 9;10(1):39. doi: 10.1038/s41514-024-00164-2. NPJ Aging. 2024. PMID: 39251602 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

336 results

Search Page

Filters